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Abstract
Background: Autoantibodies against the paranodal protein contactin-1 have recently been described in patients
with severe acute-onset autoimmune neuropathies and mainly belong to the IgG4 subclass that does not activate
complement. IgG3 anti-contactin-1 autoantibodies are rare, but have been detected during the acute onset of
disease in some cases. There is evidence that anti-contactin-1 prevents adhesive interaction, and chronic exposure
to anti-contactin-1 IgG4 leads to structural changes at the nodes accompanied by neuropathic symptoms. However,
the pathomechanism of acute onset of disease and the pathogenic role of IgG3 anti-contactin-1 is largely unknown.
Methods: In the present study, we aimed to model acute autoantibody exposure by intraneural injection of IgG of
patients with anti-contacin-1 autoantibodies to Lewis rats. Patient IgG obtained during acute onset of disease (IgG3
predominant) and IgG from the chronic phase of disease (IgG4 predominant) were studied in comparison.
Results: Conduction blocks were measured in rats injected with the “acute” IgG more often than after injection of
“chronic” IgG (83.3% versus 35%) and proved to be reversible within a week after injection. Impaired nerve conduction
was accompanied by motor deficits in rats after injection of the “acute” IgG but only minor structural changes of the
nodes. Paranodal complement deposition was detected after injection of the “acute IgG”. We did not detect any
inflammatory infiltrates, arguing against an inflammatory cascade as cause of damage to the nerve. We also did not
observe dispersion of paranodal proteins or sodium channels to the juxtaparanodes as seen in patients after chronic
exposure to anti-contactin-1.
Conclusions: Our data suggest that anti-contactin-1 IgG3 induces an acute conduction block that is most probably
mediated by autoantibody binding and subsequent complement deposition and may account for acute onset of
disease in these patients. This supports the notion of anti-contactin-1-associated neuropathy as a paranodopathy with
the nodes of Ranvier as the site of pathogenesis.
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Background
Neuropathies with autoantibodies against paranodal pro-
teins comprise a recently described subgroup of inflam-
matory neuropathies. So far, autoantibodies against the
paranodal proteins contactin-1 (CNTN1), neurofascin-155
and contactin-associated protein (Caspr) have been identi-
fied [1–5]. Most patients with anti-CNTN1 autoantibodies
show a distinct clinical phenotype of acute-onset severe
sensorimotor peripheral neuropathy, in some associated
with a disabling tremor and/or sensory ataxia [3, 4, 6].
Neuropathies with antibodies against paranodal pro-
teins are often referred to as “paranodopathies” as the
paranode is the site of immune attack [7, 8]. However,
this term was originally introduced to classify anti-
ganglioside autoantibody-associated acute motor axonal
neuropathy with reversible conduction failure and referred
to the pathophysiological concept of complement-mediated
reversible conduction block [9, 10]. Autoantibodies against
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paranodal proteins mostly belong to the IgG4 subclass
that does not activate complement, but IgG1, IgG2 and
IgG3 autoantibodies have also been described either in
combination with IgG4 or as the predominant subclass
[3, 4]. Pathogenicity of IgG4, but not of IgG1, was re-
cently demonstrated by intravenous passive transfer of
anti-CNTN1 IgG4 to rats immunised with P2 peptide
[2]. Further indicators of a pathogenic role of paranodal
autoantibodies are the destruction of paranodal archi-
tecture detectable in patients with anti-CNTN1 asso-
ciated neuropathy, the excellent therapeutic response to
rituximab and the uniform clinical phenotype of the
patients [4]. There is striking evidence that IgG4 auto-
antibodies play a pathogenic role during the course of
disease and it was shown in vitro that anti-CNTN1
autoantibodies inhibit cell adhesion, which may account
for anti-CNTN1 IgG4-induced structural damage of the
paranodes [11]. However, the pathomechanism of acute
onset of disease in these patients is still unclear, as
structural changes induced by non-inflammatory IgG4
autoantibodies are unlikely to induce an acute pheno-
type. Accordingly, an immediate effect was absent after a
single intraneural injection of anti-CNTN1 [2]. In a former
study, we could detect anti-CNTN1 IgG3 in two patients
with inflammatory neuropathy, both tested during the
acute onset of disease [12] and anti-Caspr IgG3 in a
patient with GBS phenotype [5]. We furthermore demon-
strated that binding of anti-CNTN1 induces complement
deposition and activation, related to the amount of IgG3
autoantibodies [13]. We therefore hypothesised that acute
exposure of anti-CNTN1 IgG containing IgG3 may induce
an acute neuropathy with reversible conduction failure,
corresponding to the original concept of paranodopathy.
Methods
Patients, purification of IgG and determination of IgG
subclasses
We used purified IgG of three patients with high titres
of anti-CNTN1 autoantibodies. The clinical details and
the procedure of anti-CNTN1 detection were recently
reported [4]. IgG was purified from material of thera-
peutic plasma exchange by exchange chromatography
as previously described [14]. Plasma exchange material
of two patients with optic neuritis and without evidence of
autoantibodies served as controls. The titres of IgG sub-
classes of the purified IgG were determined by enzyme-
linked immunosorbent assay (ELISA) as previously de-
scribed [4]. To determine the IgG subclass effectively
binding to the paranodes, binding assays with teased
fibres and subclass-specific FITC-conjugated secondary
antibodies (anti-human IgG3: Merck, Darmstadt, Germany;
anti-human IgG1, IgG2, IgG4: Abcam, Cambridge, UK)
were performed as previously described [4]. Ethics approval
was granted by the Ethics’ Committee of the University of
Würzburg Medical Faculty.
Animals, study design and intraneural injection
Eight-week-old female Lewis rats were obtained from
Charles River (Sulzfeld, Germany). Animals were kept in
cages with free access to water and food. All experi-
ments were approved by the Bavarian State authorities
(Regierung von Unterfranken). Intraneural injection of
10 μl of patient IgG (100 mg/ml) was performed under
anaesthesia with isoflurane by dissecting the right sciatic
nerve at the sciatic notch, following injection with a 27G
Hamilton syringe. The timeline of the experiments is
demonstrated in Fig. 1. All animals were injected at two
time-points. The week before the injection, nerve con-
duction studies (NCS) and 4 days of behavioural testing
were performed. Behavioural testing was repeated the
day after the second injection. NCS were performed
2 days after the second injection, and tissue processing
was done immediately after the NCS. To study potential
recovery of the animals from autoantibody injection, an
extended experiment was conducted in seven animals,
repeating behavioural testing and NCS twice in the week
after injection (Fig. 1b). All injections, behavioural tests
and NCS were conducted under blinded conditions. Rats
were randomised to the patient/control groups and to
the extended study by a person who was not involved in
the experiments. Blinded aliquots of patient/control IgG
were prepared by this person and the random list
remained sealed until the end of data acquisition.
Behavioural testing
For motor testing, the rats were put on an accelerating
RotaRod (TSE Systems, Bad Homburg, Germany) and
the mean latency time to fall of five trials was calculated
for each animal. For statistical comparison, the ratio of
fall latencies pre- and post-injection for each animals
was calculated and compared between patients and con-
trols. Gait analysis was performed using the Catwalk XT
(Noldus, Emmerich am Rhein, Germany), a transparent
glass runway with a camera underneath that detects the
footprints. The following parameters were calculated:
standing time, print area and maximum intensity. We
recorded three runs per animal and the mean value of
each parameter was calculated and the ratio of pre- and
post-injection values was taken. Sensory function was
assessed by von-Frey filaments. The left and right
hindpaws were tested six times each and were analysed
using Dixon’s staircase system [15].
Nerve conduction studies
All NCS were performed under intraperitoneal anaesthe-
sia with ketamine/xylazine that does not reduce F wave
persistence [16]. The left and right sciatic/tibial nerve of
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each animal was measured using Neurosoft-Evidence
3102 electromyograph (Schreiber and Tholen Medizin-
technik GmbH, Stade, Germany) and the appropriate
software. The skin temperature was maintained at
34–36 °C using a warming lamp. For motor NCS, the
recording electrodes were placed into the sole of the
hindpaw with the active electrode between the third
and fourth toe and the inactive electrode lateral to
the first toe. The distal stimulation electrodes were placed
above the ankle, the proximal stimulation electrodes at
the sciatic notch. For motor neurographies, a supramaxi-
mal stimulus was applied at the distal and proximal stimu-
lation site and the distance between both sites was used
for the calculation of the nerve conduction velocity
(NCV). F waves and H-reflexes were obtained by ten serial
supramaximal stimuli with frequencies of 0.3, 1, and
10 Hz at the distal stimulation site. The minimum F wave
latencies and the persistence of F waves was obtained for
each frequency, the persistence of H-reflexes was only
obtained at 0.3 Hz because no H-reflexes were recordable
at higher frequencies. For NCS of mixed afferents, the
stimulation electrodes were placed above the ankle and
the recording electrodes at the sciatic notch. NCV was
calculated from the distance between stimulation and
recording electrodes. Electromyography was performed in
the small foot muscles and the gastrocnemius muscles by
needle electrodes.
Histological and immunohistochemical analysis
After the last NCS, the rats were sacrificed and the sciatic
nerve was rapidly removed and was cut into three pieces:
the proximal one was mounted in Tissue-Tec and was
deeply frozen in liquid nitrogen for immunohistochemis-
try, the middle one was immediately prefixed in 4% para-
formaldehyde for 10 min for teased fibre preparations and
the distal one was fixed in glutaraldehyde for semi-thin
sections. All three pieces were supposed to be reached by
the injection as they were only millimetres apart from the
injections site. For immunohistochemical analysis of
inflammation, 20-μm cross sections were cut, fixed with
acetone for 10 min, blocked with 10% bovine serum albu-
min (BSA)/phosphate-buffered saline (PBS) for 30 min
and were incubated with the following primary antibodies
diluted in PBS with 0.3% TritonX overnight: anti-CD3
(rabbit, 1:500, Abcam), anti-C5b9 (mouse, 1:1000, Dako/
Agilent Technologies, Santa Clara, California, USA,
mouse, 1:500, Santa Cruz, Dallas, Texas, USA), anti-C1q
(mouse, 1:50, Abcam), anti-CD68 (mouse, 1:1000, Dako)
and Cy3-conjugated anti-rabbit/anti-mouse secondary
antibodies (Dianova, Hamburg, Germany). For semi-thin
sections, tissue was fixed with 4% paraformaldehyde/glu-
taraldehyde for at least 24 h, was post-fixed with 2%
osmiumtetraoxide, dehydrated by acetone and was em-
bedded in 3,4-epoxycyclohexylmethyl. Semi-thin sections
were cut using a microtome (Leica EM UC7, Leica,
Wetzlar, Germany) and were stained with azure II and
methylene-blue.
For the analysis of nodal architecture, immunofluores-
cence was performed as previously described [5]. Shortly,
slides were fixed with acetone, incubated with primary
antibodies (anti-Caspr, Abcam, 1:100; anti-pan-neurofascin,
Abcam, 1:400, anti-pan-sodium-channel, Sigma Aldrich, St.
Fig. 1 Schedule of the experiments. a Shows the standard course of experiments, in (b) an extended protocol for the study of recovery up to
9 days after injection is shown
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Louis, Missouri, USA, 1:100) overnight at 4 °C and with ap-
propriate secondary antibodies (Alexa-Fluor488-conjugated
anti-rabbit or anti-mouse IgG, 1:200, Dianova) for 2 h at
room temperature.
Immunofluorescence was analysed using a fluores-
cence microscope (Axio Imager.M2, Zeiss, Oberkochen,
Germany); semi-thin sections were analysed by light
microscopy (Olympus BH2, Olympus, Shinjuku, Japan).
Structured illumination and confocal microscopy
Immunostained teased fibres were recorded on a com-
mercially available SIM Zeiss ELYRA S.1 microscope
using a 63×/1.40 oil immersion objective. Laser illu-
mination at 568 nm was used for excitation of Cy3.
Images were recorded with structured illumination
applying five rotational and five phase variations. The
final superresolved image was reconstructed in ZEN
software (Zeiss) and rendered in Imaris (Bitplane,
Belfast, UK).
Confocal microscopy images of anti-Caspr staining of
teased fibres were recorded on a commercial LSM700
(Zeiss) setup using a 63×/1.4 oil immersion objective.
Morphometry by confocal microscopy was restricted to
a subset of four to six animals per patient. At least eight
nodes per animal were measured. The same number of
matched controls was measured in parallel with each pa-
tient animal. Z-stacks were acquired with a pixel size of
91 nm and a z-step size of 300 nm. Cy3 signal was
recorded using a DPSS laser line (555 nm) and suitable
filter settings. Z-stacks were loaded in Imaris for further
analysis. After applying intensity based thresholding
(constant thresholding values for both control and
patient), area, volume and intensities of singular Caspr
patches were exported using Excel (Microsoft). Length
measurements were performed by hand using the
section and measurement tool in Imaris. Representative
images were processed in ImageJ (FIJI distribution [17]).
Processing included linear correction using brightness
and contrast only.
Statistical analysis
Statistical analysis was performed using SPSS 23.0 (IBM,
Armonk, New York, USA). Normal distribution of data
was tested by Shapiro-Wilk test. For normally distri-
buted data, a t test was performed; for non-normally
distributed data, we used Mann-Whitney U test. Pair-
wise comparisons were done by related samples Wilcoxon
signed rank test. Statistical comparisons for microscopy
data were performed in Origin (OriginLab, Northampton,
Massachusetts, USA). Mann-Whitney U test was ap-
plied to make single comparisons between control and
patient group.
Results
Patients and antibody titres
Purified IgG of three patients with anti-CNTN1-as-
sociated neuropathy was used for the experiments.
Anti-CNTN1 autoantibodies of these three patients were
identified in a former study by ELISA and all three
patients showed distinct binding to the paranodes of
murine teased fibres and to CNTN1-transfected human
embryonic kidney 293 cells [4]. The ELISA antibody titres
of the purified IgG of the individual patients are shown in
Table 1. In one patient whose IgG was obtained during
the acute onset of disease (further referred to as “acute
patient”), IgG3 was the predominant subclass (1:7500)
with only low titres of IgG1 (1:1000) and IgG4 (1:500). In
the second patient (also recruited during the chronic
phase of disease), low titres of all four subclasses were
detectable with predominance of IgG3 (1:1000) and IgG4
(1:1000) (further referred to as “low titre patient”). The
third patient whose serum was also obtained during the
chronic phase of disease showed high titres of IgG4
(1:15,000), a moderate titre of IgG3 (1:5000) and low titres
of IgG1 (1:500) and IgG2 (1:1000) (further referred to as
“chronic patient”). Binding assays on murine teased fibres
using subclass-specific secondary antibodies revealed
IgG3 and IgG4 as the binding subclasses in the acute
patient and only IgG4 in the other two patients (Fig. 2).
IgG3 and IgG4 autoantibodies access paranodes after
intraneural injection
To confirm the binding of patient IgG to the paranodes
after intraneural injection, teased fibres of the sciatic
nerves of all rats were incubated with Cy3-conjugated
anti-human IgG. Positive binding 2 days after injection was
detectable in 33.3% of animals injected with IgG of the
acute patient, in 20% of the animals of the chronic patient
and in none of the animals injected with IgG of the low
titre patient or the control patients. Binding did not
include the whole paranodal region but was restricted to a
small band adjoining the nodes, presumably those parts of
the paranodes that are easily accessible by autoantibodies
in vivo (Fig. 3a). Structured illumination microscopy re-
vealed a tube-like arrangement of autoantibody binding,
spanning the circumference of the nerve fibres (Fig. 3b).
To further specify the subclass of IgG that binds to the
paranodes, teased fibres of rats injected with IgG of the
acute and chronic patient were incubated with anti-human
IgG3 and IgG4. In the acute patient, binding of IgG3 but
not IgG4 to the paranodes could be detected; in the
chronic patient, IgG4 but not IgG3 was the binding sub-
class, confirming the predominant IgG subclass as the
binding subclass and demonstrating that IgG3 as well as
IgG4 autoantibodies are able to access the paranodes in
vivo (Fig. 3c, d).
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Conduction blocks in animals injected with patient IgG
Conduction blocks defined as a ratio of the distal and
proximal compound muscle action potential (CMAP) of
more than 1.5 were measured in 83.3% of rats injected
with IgG of the acute patient and in 35% of rats injected
with IgG of the chronic patient, but also in 13.2% of
control animals as a side-effect of intraneural injection.
No conduction blocks were detectable in the rats
injected with IgG of the low titre patient. Loss of F
waves in combination with a normal distal CMAP, a fur-
ther indicator of proximal conduction block, was found
in 66.7% of rats injected with IgG of the acute patient
and in 40% with IgG of the chronic patient, but not in
any rat injected with IgG of the low titre patient or any
control animal. The combination of conduction block
and loss of F waves was found in 66.7% of animals of the
acute patient and in 25% of animals of the chronic
patient, not in any control (Fig. 4). Distal motor latency
did not differ between patient animals and controls. We
did not detect any conduction block or loss of F waves
prior to injection.
Accordingly, the ratio of the right distal and proximal
CMAP after injection was increased in animals injected
with IgG of the acute patient compared to control ani-
mals (p = 0.0001) and tended to be higher in animals
injected with IgG of the chronic patient in comparison
with controls (p = 0.092) but did not differ in animals
of the low titre patient. The persistence of F waves
on the right side after injection was reduced in ani-
mals of the acute and chronic patient (acute patient:
0.3 Hz p = 0.0001, 1 Hz p = 0.0001, 10 Hz p = 0.001;
chronic patient: 0.3 Hz p = 0.015, 1 Hz p = 0.024,
10 Hz p = 0.0001), not in animals of the low titre patient.
No differences of these parameters between groups were
recorded before injection or on the left side. In 41.7% of
rats injected with IgG of the acute patient, but not in any
control or other patient animal, no sensory nerve action
potential (SNAP) was recordable after injection, pre-
sumably due to a sensory conduction block. All these
animals also had a motor conduction block. We did not
detect any spontaneous activity by EMG.
Motor deficits after injection of patient IgG
Rotarod testing indicated motor deficits in rats injected
with IgG of the acute patient: here, the latency to fall
after injection in relation to latency pre-injection was
decreased compared to controls (p = 0.0058). No diffe-
rences were detectable between the fall latencies of rats
injected with IgG of the other patients and controls
(Fig. 5a).
Gait analysis with the Catwalk system showed that rats
injected with IgG of the acute patient had a decreased
Table 1 Summary of antibody titres and subclasses, electrophysiological and morphological data of rats injected with IgG of
different patients. Significant differences (between patients and controls) are marked with*








Titre of IgG subclasses (predominant subclass
in bold type)
IgG1 1:1000 1:100 1:500 Negative
IgG2 negative 1:100 1:1000
IgG3 1:7500 1:1000 1:5000
IgG4 1:500 1:1000 1:15,000
Binding subclass In vitro IgG3, (IgG4) IgG4 IgG4 None
In vivo IgG3 No binding detectable IgG4
Conduction block 83.3%* 0% 35% 13.2%
Loss of F waves 66.7%* 0% 40%* 0%
Median CMAP ratio (distal/proximal) pre-/post-injection (mV) 1.14 (1.03–1.34) 1.18 (1.04–1.24) 1.11 (0.89–1.38) 1.12 (0.88–2.49)
3.32 (1.04–20.25)* 1.18 (0.92–1.71) 1.35 (1.07–13.35) 1.23 (1.08–5.12)
Median SNAP pre-/post-injection (μV) 20.0 (6.9–29.9) 17.4 (10.0–59.9) 18.0 (0–26.1) 17.8 (2.9–106)
8.8 (0–18.7)* 13.2 (0.3–63.0) 13.7 (1.3–30.9) 15.7 (3.6–39.2)
Median fall latency (s) 205 (111–336) 230 (64–396) 231 (100–500) 223 (71–401)
155 (54–222)* 186 (76–297) 185 (84–389) 180 (67–343)
Median standing time right hind paw (s) 0.23 (0.17–0.28) 0.24 (0.19–0.37) 0.22 (0.17–0.52) 0.24 (0.15–0.46)
0.18 (0.08–0.25)* 0.24 (0.18–0.45) 0.22 (0.11–0.44) 0.24 (0.15–0.43)
Median print area right hind paw (cm2) 1.39 (0.54–2.18) 1.89 (1.04–2.74) 1.18 (0.45–1.73) 1.30 (0.64–2.35)
0.88 (0.09–2.21)* 2.07 (1.30–2.98) 1.04 (0.32–1.51) 1.61 (0.74–2.91)
Median maximum intensity right hind paw (AU) 217 (182–229) 222 (207–232) 212 (180–219) 210 (173–232)
177 (83–234)* 220 (206–234) 202 (94–221) 215 (165–235)
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relative standing time (p = 0.0040, Fig. 5b), a reduced
relative foot print area (p = 0.0003, Fig. 5c) and a re-
duced relative maximum intensity (p = 0.0013, Fig. 5d)
on the right hind paw compared to control rats, reflect-
ing limping of the right hind paw post-injection. Rats
injected with IgG of the chronic and low titre patient
did not show a relative reduction of any of these para-
meters after injection.
No differences in the von Frey testing were observed
in rats injected with patient IgG and controls (data
not shown).
Recovery of nerve conduction and motor deficits over
time
To study the time course of nerve conduction and
motor deficits after injection, three animals injected with
IgG of the acute patient and four animals injected with
IgG of a control were tested at 1, 5 and 7 days after
injection and had nerve conduction studies at 2, 6 and
8 days after injection (Fig. 1b). A conduction block, loss
of F waves and motor deficits were detectable in two of
the three rats injected with patient IgG 2 and 1 day
after injection respectively. CMAP ratios and motor
function were almost normal 6 and 5 days after injection
respectively and were entirely normal at 8 and 7 days after
injection (Fig. 6).
Alterations of paranodal proteins after injection
The distribution of the paranodal protein Caspr, the nodal
and paranodal protein neurofascin and nodal sodium
channels was studied by conventional immunofluores-
cence. We did not detect any abnormalities of sodium
channel staining, neither a dispersion of sodium channels
to the paranodes nor a weakened staining. We also did
not detect any dispersion of Caspr or neurofascin to the
juxtaparanodes or any elongated nodal gaps. As the short
time course of anti-CNTN1 application may lead to minor
alterations of signal distribution, we applied quantitative
Fig. 2 Binding assay with patients’ sera on murine teased fibres using subclass-specific secondary antibodies. No binding to paranodes is visible
after incubation with a control serum (a). The acute patient shows paranodal deposition of IgG3 and weakly of IgG4 (b). In the low titre and
chronic patient, IgG4 can be identified as the binding subclass (c, d). Bar = 20 μm
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confocal microscopy on Caspr staining of teased nerve
fibres of injected rats. Recordings revealed a modest re-
duction in signal volume, a mild reduction of length of
the nodal complex and total signal intensity in rats
treated with IgG of the acute patient, not in animals of
the other patients or controls. The length of the nodal
gap remained unchanged (Fig. 7, Additional file 1: video 1
and Additional file 2: video 2).
Inflammatory cells and complement deposition
Paranodal deposition of complement component C1q
was detectable at some nodes of animals injected with
Fig. 3 Immunofluorescence staining of sciatic nerves of rats with Cy3-conjugated anti-human IgG (a, b), FITC-conjugated anti-human IgG3 (c)
and IgG4 (d). Confocal fluorescence microscopy detects a small band of autoantibody binding at the paranodes of a patient animal (a), not in a
control animal (b). Structural illumination microscopy reveals a tube-like arrangement of autoantibodies around the axon in the patient animal (c),
not in the control animal (d). Subclass specific antibodies uncover IgG3 as the binding subclass in the acute patient (e) and IgG4 in the chronic
patient (f). Bars in (a, b, e, f) = 10 μm, in (c) and (d) 5 μm, rectangles in (c) indicate the orientation
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IgG of the acute patient that also showed paranodal IgG
deposition but not in any animal injected with IgG of
the chronic patient (Fig. 7b). A moderate increase of
macrophages, T cells and C5b9 deposition was detect-
able in nerves on the right side compared to the left and
may be induced by an inflammatory response to the in-
jection (data not shown). We did not detect any diffe-
rences between animals treated with patient IgG or
control IgG, arguing against an inflammation-induced
damage to the nerve fibres.
Semi-thin sections revealed acute Wallerian degene-
ration of some nerve fibres, probably due to mechanical
damage. There were no differences between control and
patient IgG injected animals (data not shown).
Discussion
In this study, we detected conduction blocks and motor
deficits in rats intraneurally injected with IgG of patients
with anti-CNTN1-associated neuropathy. By choosing a
short-term and focal application of IgG, we were able to
demonstrate reversible conduction blocks accompanied by
complement deposition, motor dysfunction, fitting with
the original concept of paranodopathy as an autoantibody-
mediated reversible dysfunction of the node of Ranvier.
Fig. 4 Summary of results of nerve conduction studies (NCS). Sciatic motor NCS were performed by stimulating above the ankle (distal site) or at
the sciatic notch (proximal site) and recording from the sole (a). Stimulation sites are marked by arrows, the recording site by the asterisk. Almost
equal CMAP amplitudes were measured in controls (b), conduction blocks defined as a ratio of the distal to proximal CMAP of > 1.5 were found
in patient animals (c). The ratio of distal to proximal CMAP was increased in animals injected with IgG of the acute patients compared to controls
(d). F waves following the CMAP were measured in controls (e), whereas loss of F waves was found in patient animals (f). F wave persistence was
mostly normal (70–100%, black) in animals injected with IgG of the low titre patient and controls, whereas complete loss of F waves (white) was
found in the majority of animals injected with IgG of the acute patient and many animals injected with IgG of the chronic patient (g)
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Even though the concept of paranodopathy has been
expanded to the spectrum of IgG4-autoantibody-mediated
neuropathies in the last years, our data give evidence that
at least during the acute onset of disease reversible
conduction block may be induced.
When comparing the effect of IgG of the acute phase
of disease (predominantly IgG3) with IgG of the chronic
phase (predominantly IgG4), we found a more severe
effect of the “acute IgG”. This observation supports
the idea of acute conduction block induced by auto-
antibody binding that has been extensively studied in
anti-ganglioside-associated neuropathies [10, 18]. As
described in studies on anti-ganglioside antibodies,
deposition of C1q was detectable at the paranodes of
rats injected with IgG of the acute patient. No C1q
was detectable at paranodes of rats injected with IgG
of the chronic patient, although complement binding
was demonstrated in vitro in another study using sera
of the very same patient [13]. This is most probably ex-
plained by the observation of IgG4 as the binding subclass
and lack of detection of paranodal IgG3 binding in this
patient. However, complement deposition was not detec-
table at all nodes. This might be a failure of detection due
to temporary or only mild complement deposition on just
those nodes that were reached by diffusion of IgG. In
contrast to gangliosides that are found at the nodes and
paranodes, CNTN1 is restricted to the paranodes that are
not as easily accessible. This is most probably also the
reason why we could only detect autoantibody binding in
a small band not comprising the whole paranodal region.
This observation is well in line with a previous study that
demonstrated that binding to the complete paranodal
region can only be seen after 3 days of antibody exposure
[2]. The lifespan of anti-CNTN1 after intraneural injection
Fig. 5 Box plots of parameters of motor testing. The y-axis gives the values after injection in relation to pre-testing values (in %). Fall latency
measured by rotarod is decreased in animals injected with IgG of the acute patient (a). Catwalk gait analysis reveals decreased standing time,
print area and maximum intensity of the right hind paw in animals injected with IgG compared to controls (b–d). The boxplots show medians
and quartiles; circles represent outliers. (*0.1 > p > 0.01, **0.01 > p > 0.001, ***0.001 > p)
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was shown to be small with a significant decrease after
3 days [2]. So complement deposition may not be detect-
able anymore at all nodes at the day of tissue harvesting,
impeded by autoantibody binding only to a small area of
the paranode. Alternatively, autoantibodies may induce
temporary axo-glial detachment, leading to leakage of
driving currents that may contribute to conduction
failure. The lack of spontaneous muscle activity in our
animals supports the idea of a short-term pathogenic
effect by conduction block without any axonal damage.
Predominance of motor conduction deficits and motor
dysfunction reflects the clinical phenotype of the patients
who all suffered from motor more than sensory peripheral
neuropathy [4].
It has been shown in vitro that anti-CNTN1 auto-
antibody binding of patients with predominance of IgG4
prevents adhesive interaction between CNTN1 and its
binding partners Caspr and neurofascin-155 [11]. Structural
changes of the paranodal region are therefore supposed to
be involved in the pathogenicity of anti-CNTN1-associated
Fig. 6 Change of NCS and motor testing parameters over time of three rats injected with IgG of the acute patient in comparison to four
controls. Increase of distal/proximal CMAP ratio (a) and decrease of SNAP (b), standing time (c), print area (d), maximum intensity (e) and fall
latency (f) of the right hind paw are detectable in two rats 1/2 days after injection and are almost normal four days later. Rat 3 did not show any
effect (probably due to technical problems)
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neuropathy. Several studies demonstrated disruption of
the paranodes in patients with anti-CNTN1-associated
neuropathy [4, 19]. In contrast to studies of human
nodal architecture, that demonstrated elongated nodes,
a dispersion of paranodal proteins and sodium channels
and a weakened staining of Caspr and neurofascin [4],
we only detected a slightly reduced volume and sum
intensity of paranodal proteins accompanied with minor
differences of length of the nodal complex, no elongated
nodes or dispersion of proteins. This is most probably
explained by the short time course. Structural changes, as
shown to be induced by anti-CNTN1 IgG after incubation
for 36 h in vitro [11], may need a longer exposure to auto-
antibodies in vivo and it was shown that anti-CNTN1
autoantibodies have a short lifespan in vivo [2]. Re-
duced sum intensity and volume of Caspr staining, the
paranodal binding partner of CNTN1, may be the
result of cross-linking IgG3 autoantibodies that induce
internalisation. However, the exact pathomechanisms
need to be explored in future studies.
Our data provide new insights into the pathogenicity of
acute autoantibody exposure in anti-CNTN1-associated
neuropathy and extend recent findings that were obtained
by a study from Manso et al.: by modelling chronic auto-
antibody exposure using intravenous application, they
demonstrated a pathogenic effect of IgG4 anti-CNTN1,
leading to exacerbation of neuropathy in animals immu-
nised with P2 protein [2]. They did not succeed in indu-
cing conduction block after intraneural injection of IgG4
or IgG1 anti-CNTN1 [2]. This can be explained by diffe-
rences of IgG subclasses: the strongest effect in our study
was measured in the acute patient with a high titre of
IgG3 anti-CNTN1 and the chronic patient also had a
relevant titre of IgG3.
Data of the study by Manso et al. and ours taken to-
gether support the idea that binding of IgG3 anti-CNTN1
Fig. 7 Confocal microscopy image of paranodes and box plots illustrating morphometric data and complement deposition of the acute patient.
Paranodal immunofluorescence staining with anti-Caspr is reduced at paranodes of rats injected with IgG of the acute patient (a, lower image)
compared to paranodes of a control rat (a, upper image). Scale bar = 10 μm. Complement deposition at the paranodes can be detected by
immunofluorescence staining with anti-C1q (b). Morphometric analysis revealed a reduction of sum intensity (c), length of the nodal complex (d)
and paranodal volume (e) in rats injected with IgG of the acute patient compared to control rats. (*0.1 > p > 0.01, **0.01 > p > 0.001, ***0.001 > p)
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as a complement-activating IgG subclass leads to an acute
conduction block that is detectable after short-term injec-
tion and that IgG4 pathogenicity requires chronic auto-
antibody exposure. Acute onset of disease may display the
clinical correlate of IgG3-mediated pathogenicity, whereas
the chronic course of disease could be explained by effect
of IgG4. Accordingly, the serum of the patient with pre-
dominance of IgG3 was obtained during the acute begin-
ning of the disease, whereas the sera of the two other
patients with IgG4 were obtained after several years of
neuropathic symptoms as described in a previous study
[4]. Similarly, anti-MUSK autoantibodies of patients with
myasthenia gravis that are also of the IgG4 subclass in-
duce symptoms in passive transfer experiments of rats
only after approximately 14 days of regular injection [20],
whereas passive transfer experiments of IgG of patients
with presumably acetylcholine receptor autoantibodies
showed clinical symptoms after 2 to 7 days of injection
and a reduction of amplitudes of miniature end-plate
potentials as early as 12–21 h after a single injection [21],
implying that acetylcholine receptor autoantibodies
that mostly belong to the subclass IgG1 lead to more
acute symptoms compared to anti-MUSK IgG4, pro-
bably due to an acute inflammatory response including
complement deposition.
Conduction blocks as well as loss of F waves were
not found in all animals injected with the same patient
IgG in our study. This may be explained by technical
reasons: intraneural injection might have only reached
the epineurium in these animals or IgG might have
not reached the whole cross-section area of the sciatic
nerve, depending on the individual anatomy of each
animal. Rare conduction blocks in control animals can
be explained by iatrogenic lesions of the nerve by the
injection itself, supporting the importance of a control
group in this kind of experiments. Another limitation
of our study is that total IgG instead of purified sub-
classes were used for injection. Therefore, it cannot be
proven that higher effects in the acute patients are due
to the IgG3 subclass. However, IgG3 was identified as
the binding subclass in this patient, supporting the
assumption that binding of IgG3 is pathogenic.
We did not find evidence of an inflammatory re-
action induced by autoantibody binding, although
complement deposition was detectable at the para-
nodes and is known to induce inflammatory response
[22] and also did not find any relevant axonal degene-
ration. This finding argues against an inflammation-
induced paranodal damage and leads to the suspicion
of conduction block induced by autoantibody binding
and temporary complement deposition only. The latter
is supported by the quick recovery of the animals after
a few days and the lack of spontaneous activity in
EMG recordings.
Conclusions
In summary, our data give evidence of an early pathogenic
effect of anti-contactin-1 IgG3 rather than IgG4 after
short-term exposure. Autoantibody binding and comple-
ment deposition rather than inflammatory responses or
structural damage appear to underlie this effect. Different
pathomechanisms may contribute to the clinical picture
of anti-CNTN1-associated neuropathy, possible at diffe-
rent stages of disease and should be taken into account in
therapeutic approaches.
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